Sapient Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.95M Sell
18,011
-981
-5% -$435K 0.12% 89
2026
Q1
$8.48M Sell
18,992
-15,332
-45% -$7.15M 0.13% 94
2025
Q4
$15.6M Buy
34,324
+13
+0% +$5.6K 0.22% 71
2025
Q3
$13.6M Sell
34,311
-1,999
-6% -$835K 0.21% 73
2025
Q2
$16.2M Buy
36,310
+314
+0.9% +$145K 0.29% 64
2025
Q1
$17.5M Buy
35,996
+200
+0.6% +$93.2K 0.34% 60
2024
Q4
$14.4M Buy
35,796
+498
+1% +$231K 0.28% 67
2024
Q3
$16.4M Buy
35,298
+43
+0.1% +$20.7K 0.33% 59
2024
Q2
$16.5M Sell
35,255
-20
-0.1% -$8.68K 0.34% 56
2024
Q1
$14.7M Buy
35,275
+789
+2% +$334K 0.33% 64
2023
Q4
$14M Buy
+34,486
New +$12.7M 0.36% 61

Other funds holding VRTX

Sapient Capital's VRTX Position: Q2 2026 in Review

Sapient Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 5.2% in Q2 2026, selling an estimated $435K and leaving 18,011 shares worth $8.95M. The position accounts for 0.12% of the portfolio, ranked #89.

Sapient Capital first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $17.5M in Q1 2025. 256 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Sapient Capital held 18,011 shares of Vertex Pharmaceuticals worth $8.95M as of Q2 2026.
  • Sapient Capital sold 981 Vertex Pharmaceuticals shares in Q2 2026, an estimated $435K.
  • Vertex Pharmaceuticals made up 0.12% of Sapient Capital's portfolio in Q2 2026, its #89 holding.
  • Sapient Capital first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Sapient Capital's Vertex Pharmaceuticals position peaked at $17.5M in Q1 2025.
  • 256 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sapient Capital's 13F filing for Q2 2026, filed 9 Jul 2026.